Overview

NCI Definition [1]:
A preparation composed of three separate DNA plasmids encoding the tumor-associated antigens (TAAs) Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), with potential immunostimulating and antineoplastic activites. Upon intramuscular delivery and electroporation of the WT1/PSMA/hTERT-encoding plasmid DNA INO-5401, the genes are translated into their respective proteins inside the cell. The expressed proteins activate the immune system and induce a cytotoxic T-lymphocyte (CTL)-mediated response against cells expressing the WT1, PSMA and hTERT antigens, causing tumor cell lysis. hTERT, WT1 and PSMA are upregulated in many cancer cell types.

Ino-5401 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ino-5401, 1 is phase 1/phase 2 (1 open).

Urothelial carcinoma is the most common disease being investigated in ino-5401 clinical trials [2].

Drug Details

Synonyms [2]:
ino 5401, ino5401, wt1/psma/htert-encoding plasmid dna ino-5401
NCIT ID [1]:
C148480

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.